Latest From Kate Rawson
Amid the COVID-19 pandemic, Richard Pazdur doesn’t want the cancer patient forgotten. His solution: keep churning out approvals.
Richard Pazdur wants the oncology community to take a fresh look at US FDA’s expedited review programs. One big question: should there be fewer of them?
After slow start early in SARS-CoV-2 pandemic, CURE ID now has more than 150 case reports of drugs to treat the coronavirus.
The move means Hylton Joffe can focus exclusively on his role as director of the Office of Rare Diseases.
The agency historically has had challenges recruiting experts for its advisory committees. With most everyone working from home during COVID-19, that task was just made easier, 3D Communications’ Jim DiBiasi says.
While a vaccine candidate is still months away, US FDA is already working to identify manufacturing capacity, CBER’s Peter Marks says in an interview.